Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

What can independent research for mesothelioma achieve to treat this orphan disease?

Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Opin Investig Drugs. 2019 Jul 1:1-14. doi: 10.1080/13543784.2019.1638363. [Epub ahead of print]

PMID:
31262194
2.

The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks.

Albelazi MS, Martin PR, Mohammed S, Mutti L, Parsons JL, Elder RH.

Genes (Basel). 2019 Apr 23;10(4). pii: E315. doi: 10.3390/genes10040315.

3.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

4.

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.

Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L.

Int J Mol Sci. 2019 Jan 19;20(2). pii: E429. doi: 10.3390/ijms20020429.

5.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
6.

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.

Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M.

J Transl Med. 2018 Oct 13;16(1):282. doi: 10.1186/s12967-018-1650-0.

7.

A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.

Oliveto S, Alfieri R, Miluzio A, Scagliola A, Secli RS, Gasparini P, Grosso S, Cascione L, Mutti L, Biffo S.

Cancer Res. 2018 Oct 15;78(20):5741-5753. doi: 10.1158/0008-5472.CAN-18-0655. Epub 2018 Aug 2.

8.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

PMID:
29966799
9.

Surgery for malignant pleural mesothelioma: an international guidelines review.

Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, Mutti L, Melfi F.

J Thorac Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. Review.

10.

Insight into glucocorticoid receptor signalling through interactome model analysis.

Bakker E, Tian K, Mutti L, Demonacos C, Schwartz JM, Krstic-Demonacos M.

PLoS Comput Biol. 2017 Nov 6;13(11):e1005825. doi: 10.1371/journal.pcbi.1005825. eCollection 2017 Nov.

11.

Immunotherapy advances for mesothelioma treatment.

Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Review.

PMID:
28724330
12.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Opin Investig Drugs. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. Review.

PMID:
28679291
13.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

14.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.

Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.

15.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, Zeef L, Schwartz JM, Mutti L, Demonacos C, Krstic-Demonacos M.

PLoS One. 2017 Jun 5;12(6):e0178606. doi: 10.1371/journal.pone.0178606. eCollection 2017.

16.

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A.

Stem Cell Res Ther. 2017 May 25;8(1):119. doi: 10.1186/s13287-017-0573-7.

17.

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.

Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.

18.

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.

Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25.

PMID:
28343162
19.

Anti-CTLA-4 therapy for malignant mesothelioma.

Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L.

Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Review.

PMID:
28231719
20.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

Supplemental Content

Loading ...
Support Center